Literature DB >> 28188432

Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.

Mei Jin1, Zi-Wen Long2,3, Jing Yang1, Xiang Lin1.   

Abstract

This case-control study aims to investigate the correlations of insulin-like growth factor receptor 1 (IGF-1R) and cyclooxygenase 2 (COX-2) expressions with Ras and BRAF genetic mutations, clinicopathological features and prognosis of colorectal cancer (CRC) patients. A total of 213 CRC patients (case group) and 200 healthy individuals (control group) were selected from our hospital. Ras (K-Ras/N-Ras) and BRAF genetic mutations were detected by direct sequencing. The positive expression rates of IGF-IR and COX-2 in CRC and normal tissues were detected using immunohistochemistry. RT-qPCR and Western blotting were applied to detect the mRNA and protein expressions of IGF-IR and COX-2 in CRC tissues and normal tissues. Total mutation rate of N-Ras, BRAF and K-Ras in case group were 5.2%, 12.2% and 47.4%, respectively. The expressions of IGF-IR and COX-2 were higher in CRC tissues with Ras and BRAF mutations than in those without. CRC tissues with Ras mutation showed higher COX-2 expression than those with BRAF mutation. IGF-IR and COX-2 expressions were correlated to infiltration degree, lymphatic metastasis (in CRC tissues with and without Ras and BRAF mutations), and Dukes stages (only in CRC tissues with Ras and BRAF mutations). CRC patients with negative expressions of IGF-IR and COX-2 had significantly higher accumulative survival rate and longer mean survival duration than those with positive expressions of IGF-IR and COX-2. These findings indicate that IGF-1R and COX-2 expressions may be associated with Ras and BRAF genetic mutations, clinicopathological feature and prognosis of CRC patients.

Entities:  

Keywords:  BRAF mutation; Clinicopathological feature; Cyclooxygenase 2; Insulin-like growth factor receptor 1; Prognosis; Ras mutation

Mesh:

Substances:

Year:  2017        PMID: 28188432     DOI: 10.1007/s12253-017-0195-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.

Authors:  R Labianca; B Nordlinger; G D Beretta; A Brouquet; A Cervantes
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

3.  IGF-I enhances α5β1 integrin expression and cell motility in human chondrosarcoma cells.

Authors:  Chi-Ming Wu; Te-Mao Li; Sheng-Feng Hsu; Yi-Chang Su; Shung-Te Kao; Yi-Chin Fong; Chih-Hsin Tang
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

Review 4.  Dukes' classification of rectal cancer.

Authors:  D P Sarma
Journal:  South Med J       Date:  1988-03       Impact factor: 0.954

5.  COX2 overexpression is a prognostic marker for Stage III breast cancer.

Authors:  Hee Sung Kim; Hyeong-Gon Moon; Wonshik Han; Cha Kyung Yom; Woo Ho Kim; Jun Ho Kim; Dong-Young Noh
Journal:  Breast Cancer Res Treat       Date:  2011-04-28       Impact factor: 4.872

6.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

7.  Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.

Authors:  Oliver Stoeltzing; Wenbiao Liu; Fan Fan; Christine Wagner; Kathrin Stengel; Ray J Somcio; Niels Reinmuth; Alexander A Parikh; Daniel J Hicklin; Lee M Ellis
Journal:  Cancer Lett       Date:  2007-10-22       Impact factor: 8.679

8.  Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells.

Authors:  Ju-Fang Liu; Yi-Chin Fong; Chih-Shiang Chang; Chun-Yin Huang; Hsien-Te Chen; Wei-Hung Yang; Chin-Jung Hsu; Long-Bin Jeng; Chih-Yi Chen; Chih-Hsin Tang
Journal:  Mol Cancer       Date:  2010-02-23       Impact factor: 27.401

9.  Meta-analyses of colorectal cancer risk factors.

Authors:  Constance M Johnson; Caimiao Wei; Joe E Ensor; Derek J Smolenski; Christopher I Amos; Bernard Levin; Donald A Berry
Journal:  Cancer Causes Control       Date:  2013-04-06       Impact factor: 2.506

10.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

View more
  7 in total

1.  The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He; Lieven Thorrez; Geraldine Siegfried; Sandra Meulemans; Serge Evrard; Sabine Tejpar
Journal:  Oncogene       Date:  2020-03-06       Impact factor: 9.867

2.  Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.

Authors:  Madhav Madurantakam Royam; Chellan Kumarasamy; Siddhartha Baxi; Ajay Gupta; Nachimuthu Ramesh; Gothandam Kodiveri Muthukaliannan; Rama Jayaraj
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

3.  Urinary PGE-M Levels and Risk of Ovarian Cancer.

Authors:  Mollie E Barnard; Alicia Beeghly-Fadiel; Ginger L Milne; Eftitan Y Akam; Andrew T Chan; A Heather Eliassen; Bernard A Rosner; Xiao-Ou Shu; Kathryn L Terry; Yong-Bing Xiang; Wei Zheng; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-06       Impact factor: 4.254

4.  Oral Administration of Microencapsulated B. Longum BAA-999 and Lycopene Modulates IGF-1/IGF-1R/IGFBP3 Protein Expressions in a Colorectal Murine Model.

Authors:  Nancy Valadez-Bustos; Eleazar M Escamilla-Silva; Francisco J García-Vázquez; Marco A Gallegos-Corona; Silvia L Amaya-Llano; Minerva Ramos-Gómez
Journal:  Int J Mol Sci       Date:  2019-08-31       Impact factor: 5.923

5.  Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety.

Authors:  Jintian Song; Yi Wang; Hui Yu; Liang Zheng; Xiongchao Cai; Yigui Chen
Journal:  Comput Math Methods Med       Date:  2021-12-09       Impact factor: 2.238

Review 6.  Interactions of Colorectal Cancer, Dietary Fats, and Polymorphisms of Arachidonate Lipoxygenase and Cyclooxygenase Genes: A Literature Review.

Authors:  Maryam Gholamalizadeh; Nazanin Majidi; Shirin Tajaddod; Sepideh Abdollahi; Seyed Mohammad Poorhosseini; Mina Ahmadzadeh; Mohammad Naimi Joubani; Samaneh Mirzaei Dahka; Hanieh Shafaei; Mogge Hajiesmaeil; Atiyeh Alizadeh; Saeid Doaei; Anahita Houshiar-Rad
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

7.  The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer.

Authors:  Zhenling Zhang; Yuxin Zhang; Si Lao; Jian Qiu; Ziang Pan; Xiaoying Feng
Journal:  BMC Cancer       Date:  2022-08-05       Impact factor: 4.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.